Skip to main content
Category

Treatments

JTO Clinical and Research Reports
ResearchTreatments

Brief Report: Comprehensive Clinicogenetic Profiling of Small Cell Transformation from EGFR-mutant NSCLC Informs Potential Therapeutic Targets

*December 2023* Introduction NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports showed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses showed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been…
laurabbook@gmail.com
March 20, 2024
OncLive
ResearchTreatments

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

*December 2023* Note: Amivantamab and Lazertinib may soon receive approval as a first-line treatment for EGFR+ lung cancer. A supplemental biologics license application and new drug application seeking the approval of amivantamab-vmjw (Rybrevant) plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic non–small cell lung…
laurabbook@gmail.com
March 20, 2024
Medical Xpress
ResearchTreatments

Overcoming drug resistance with EAI-432, an allosteric EGFR inhibitor for non-small cell lung cancer

*November 2023* Note: Allosteric inhibitors are an exciting new possibility to treat osimertinib resistance but are still in preclinical stage of development. Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC)driven by mutations in the EGFR gene, particularly the L858R mutation…
laurabbook@gmail.com
March 19, 2024
OncLive
ResearchTreatments

Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results

*November 2023* Although biomarker testing is crucial for determining optimal targeted therapies for patients with advanced non–small cell lung cancer (NSCLC), the time between conducting these tests and receiving results poses challenges for both oncologists and patients, according to Stephen V. Liu, MD. “There are cases where we need to…
laurabbook@gmail.com
December 27, 2023
OncLive
ResearchTreatments

Discussing Biomarkers and Best Options in NSCLC

*November 2023* In this video, Hossein Borghaei, MS, DO, chief of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic malignancies, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium®.…
laurabbook@gmail.com
December 27, 2023